With the widespread use of CRT in rectal cancer, we now encounter increasing numbers of patients who reach pCR. Therefore, if a rectal cancer patient who has undergone CRT and subsequent surgery is documented as pCR, then a preferable prognosis can be anticipated. These patients are known to carry a very low risk of lymph node (LN) metastasis and to experience excellent overall and disease-free survival. Moreover, approximately 10–30% of rectal cancer patients achieve pathological complete remission (pCR) after CRT. It has been proven to reduce local tumor recurrence and toxicity when compared with post-operative chemoradiation therapy. Neoadjuvant concurrent chemoradiation therapy (CRT) has been increasingly used to treat locally advanced rectal cancer. Ĭompeting interests: The authors have declared that no competing interests exist. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are creditedĭata Availability: All relevant data are within the paper and its supporting information files.įunding: This study (15) was supported by a grant from the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea. Received: AugAccepted: DecemPublished: January 5, 2016Ĭopyright: © 2016 Kim et al. Lee Moffitt Cancer Center & Research Institute, UNITED STATES PLoS ONE 11(1):Įditor: Domenico Coppola, H. (2016) MRI Risk Stratification for Tumor Relapse in Rectal Cancer Achieving Pathological Complete Remission after Neoadjuvant Chemoradiation Therapy and Curative Resection. Citation: Kim H, Myoung S, Koom WS, Kim NK, Kim M-J, Ahn JB, et al.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |